Oxidative Stress and Inflammatory Biomarkers in Gaucher Disease

Eligibility Criteria

• 1. All participants must be 18 years or older.
• 2. All enrollees must understand and cooperate with requirements of the study in the opinion of the investigators and must be able to provide written informed consent.
• 3. Individuals with Gaucher disease who are medically stable for participation in study in the opinion of the investigator.
• 4. GD subjects must be stable on a specific ERT and/or SRT therapy at a specific dose (for e.g. on a units/kg basis) for at least 2 years or be naïve to these therapies (no therapy for 2 years).
• 5. GD1 patients, who have had a change in therapy i.e. a change in dose or switch from one drug to another, can be enrolled after at least 6 months have elapsed since the change and is considered stable in the opinion of the clinician providing care to the patient.
• 6. All participants must not have taken antioxidants coenzyme Q-10, vitamin C, or vitamin E for 3 weeks prior to the study.
• 1. Medically unstable conditions in any group as determined by the investigators
• 2. Concurrent disease; medical condition; or an extenuating circumstance that, in the opinion of the investigator, might compromise subject safety, study compliance, completion of the study, or the integrity of the data collected for the study.
• 3. Females who are pregnant or lactating or of child-bearing age who are not using acceptable forms of contraception
• 4. History of asthma that is presently being treated
• 5. Subjects who cannot or are unwilling to have blood drawn
• 6. Unable to adhere to study protocol for whatever reason